

20th May, 2019

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,


Sub.: Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2019

The presentation on audited Financial Results for the quarter and year ended 31st March, 2019 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q4 FY 2018-19



Consolidated Revenues for Q4 2018-19

(` Crore)

Particulars	Q4 1819	Q4 1718	Gr%
India	754	693	9%
US	372	307	21%
Brazil	205	215	-4%
Germany	240	234	2%
Other	178	132	35%
Others (Incl contract Mfg.)	107	127	-16%
Total	1,856	1,708	9%



Consolidated Revenues for FY 2018-19

(` Crore)

Particulars	YTD 1819	YTD 1718	Gr%
India	3,234	2,351	38%
US	1,589	1,100	45%
Brazil	689	709	-3%
Germany	1,009	860	17%
Other	680	522	30%
Others (Incl contract Mfg.)	472	408	16%
Total	7,673	5,950	29%

